141 related articles for article (PubMed ID: 31778105)
1. Safety Profiles and Pharmacovigilance Considerations for Recently Patented / Approved Anticancer Drugs.
Baldo P
Recent Pat Anticancer Drug Discov; 2019; 14(3):202. PubMed ID: 31778105
[No Abstract] [Full Text] [Related]
2. Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Lung Cancer.
Bearz A; Cecco S; Francescon S; Re FL; Corona G; Baldo P
Recent Pat Anticancer Drug Discov; 2019; 14(3):242-257. PubMed ID: 31362665
[TBL] [Abstract][Full Text] [Related]
3. Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Advanced Thyroid Cancer.
Vaccher E; Schioppa O; Martellotta F; Fornasier G; Giacomin E; Re FL; Baldo P; Corona G; Gobitti C
Recent Pat Anticancer Drug Discov; 2019; 14(3):226-241. PubMed ID: 31362663
[TBL] [Abstract][Full Text] [Related]
4. Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma.
Basile D; Lisanti C; Pizzichetta MA; Baldo P; Fornasier G; Lo Re F; Corona G; Puglisi F
Recent Pat Anticancer Drug Discov; 2019; 14(3):203-225. PubMed ID: 31362664
[TBL] [Abstract][Full Text] [Related]
5. Clinical Trials: Nursing Roles During the Approval Process and Pharmacovigilance of Biosimilars.
Sugay J
Clin J Oncol Nurs; 2018 Oct; 22(5):27-32. PubMed ID: 30239528
[TBL] [Abstract][Full Text] [Related]
6. Biosimilar safety considerations in clinical practice.
Choy E; Jacobs IA
Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
[TBL] [Abstract][Full Text] [Related]
7. I-SPY 2 may change how clinical trials are conducted: researchers aim to accelerate approvals of cancer drugs.
Printz C
Cancer; 2013 Jun; 119(11):1925-7. PubMed ID: 23695808
[No Abstract] [Full Text] [Related]
8. How are we assessing the safety and quality use of medicines used by young people in Australia?
Bell J; Wilson A; Elshaug A; Nassar N
J Paediatr Child Health; 2018 Jul; 54(7):718-719. PubMed ID: 28488749
[No Abstract] [Full Text] [Related]
9. Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation.
Omae K; Kataoka Y; Tsujimoto Y; Tsutsumi Y; Yamamoto Y; Fukuhara S; Furukawa TA
BMC Cancer; 2019 Oct; 19(1):998. PubMed ID: 31651263
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 clinical trials nursing: determining safety and side effects on the road approval.
Lindberg D
ONS Connect; 2012 Jul; 27(7):10-4. PubMed ID: 22855983
[No Abstract] [Full Text] [Related]
11. Clinical endpoints in trials of drugs for cancer: time for a rethink?
Koopmans PP
BMJ; 2002 Jun; 324(7350):1389-91. PubMed ID: 12052814
[No Abstract] [Full Text] [Related]
12. A Significant Anticancer Drug Approval Lag Between Japan and the United States Still Exists for Minor Cancers.
Yamashita K; Kaneko M; Narukawa M
Clin Pharmacol Ther; 2019 Jan; 105(1):153-160. PubMed ID: 29882302
[TBL] [Abstract][Full Text] [Related]
13. Toward a Personalized Use of Paclitaxel.
Russo GL
Recent Pat Anticancer Drug Discov; 2019; 14(4):296-297. PubMed ID: 31920185
[No Abstract] [Full Text] [Related]
14. 21st-Century Oncology Drug Safety via New-Age Regulatory Standards and Practices.
Pitts PJ; Le Louet H; Katz G
Ther Innov Regul Sci; 2019 Sep; 53(5):701-705. PubMed ID: 30392396
[TBL] [Abstract][Full Text] [Related]
15. Non-inferiority trials: why oncologists must remain wary.
Burotto M; Prasad V; Fojo T
Lancet Oncol; 2015 Apr; 16(4):364-6. PubMed ID: 25846084
[No Abstract] [Full Text] [Related]
16. An FDA oncology view of juvenile animal studies in support of initial pediatric trials for anticancer drugs.
Leighton JK; Saber H; Reaman G; Pazdur R
Regul Toxicol Pharmacol; 2016 Aug; 79():142-143. PubMed ID: 26952647
[No Abstract] [Full Text] [Related]
17. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.
Kesselheim AS; Myers JA; Avorn J
JAMA; 2011 Jun; 305(22):2320-6. PubMed ID: 21642684
[TBL] [Abstract][Full Text] [Related]
18. Big Data and Pharmacovigilance: The Role of Oncology Nurses.
Glenn DG
Clin J Oncol Nurs; 2016 Oct; 20(5):478-80. PubMed ID: 27668367
[TBL] [Abstract][Full Text] [Related]
19. Liposomal drug formulations in cancer therapy: 15 years along the road.
Slingerland M; Guchelaar HJ; Gelderblom H
Drug Discov Today; 2012 Feb; 17(3-4):160-6. PubMed ID: 21983329
[TBL] [Abstract][Full Text] [Related]
20. Early accelerated approval for highly targeted cancer drugs.
Chabner BA
N Engl J Med; 2011 Mar; 364(12):1087-9. PubMed ID: 21428763
[No Abstract] [Full Text] [Related]
[Next] [New Search]
